When compared to 18F-FDG in radioiodine refractory thyroid cancer patients, PSMA radioligands showed conflicting results, since Lawn-Heath and colleagues reported the superior performance of 18F-FDG both in DTC patients and in dedifferentiated thyroid cancer patients [42], but other authors reported similar results between the two examinations or a slight superiority in favour of PSMA radioligand PET/CT [40,43,45]. The gene discussed is FOLH1; the disease is thyroid gland carcinoma.